All In Biotech

Drug Trial Radar · NCT02113163

PK Study Comparing Metformin Eicosapentaenoate to a Combined Dose of Metformin Hydrochloride and Ethyl Ester EPA

An Open-label, Single and Repeat Single Ascending Dose Escalation Study to Compare the Pharmacokinetics of Metformin Eicosapentaenoate With Metformin Hydrochloride and Icosapent Ethyl Following Oral Administration to Healthy Volunteers

Last checked: Nov 20, 2026Latest source record: May 2, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

32

Planned (sponsor's estimate)

Start

Mar 2014

Primary completion

Jun 2014

Study completion Jul 2014

Sponsor

Lead sponsor
Thetis Pharmaceuticals LLCIndustry
Sponsor type
Industry
First posted
Apr 14, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The primary objective of the study is to contrast the pharmacokinetic profiles of metformin and EPA delivered separately as co-administered products (metformin hydrochloride or Glucophage and icosapent ethyl or Vascepa) and together as the solid dose form (metformin eicosapentaenoate or TP-101) under fasted and fed conditions. A secondary objective is to evaluate the safety and tolerability of single and repeat single doses of TP-101.

Conditions

  • Diabetes Mellitus, Non-Insulin-Dependent
  • Hypertriglyceridemia

Interventions

  • Metformin EicosapentaenoateDrug

  • Metformin HCl and VascepaDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. AUC following single and repeat single oral administration of metformin eicosapentaenoate, metformin hydrochloride and VascepaTime frame: PK samples at 0, 0.5, 1, 2, 4, 8, and 12 hours following drug administration

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Pennington Biomedical Research Center

    Baton Rouge, Louisiana

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.